



Presenting:

Is This Thing Safe?

Decision Analysis in Consumer Product Safety

Jeremy Jokinen

DAAG Conference 2013

DAAG is the annual conference of the SDP.

To find out more about SDP or to become a member, visit

www.decisionprofessionals.com

Johnson & Johnson

FAMILY OF CONSUMER COMPANIES

Is This Thing Safe?

Decision Analysis in Consumer Product Safety

Jeremy Jokinen, MS, PStat

Director of Safety Decision Analytics

April 2013

Overview:



Overview

- Product safety built-in to design/manufacture and testing of pre-marketed medicinal and medical device products
 - Limited patient exposure
 - Selected patient exposure (biased sample)
- Post-market, need to conduct surveillance to insure safety of products

Post-Market Surveillance

- Consumer contacts need to be monitored for potential product safety issues
- Job #1: Identify potential safety issues for marketed products and take action as quickly as possible


Surveillance

- Quantity and Quality of consumer contacts:

“I tried this product and every time I use this product I get a urinary tract infection.”

“It tastes kind of funny.”

“Upon using this cream it stung and removed my nail polish.”



Lots of Data, Little time

- Call center now internet both
- Inconsistent data/missing data
- Inconsistently applied data evaluation criteria
- Regulatory responsibility
- Consumer responsibility

**Our commitment to the consumer is that our products are safe
and effective**

What constitutes a safety signal?

- Could be a single event
 - Serious medical event temporally associated with use of product
 - Medical Determination
- Could be a huge spike in reports of events
 - Product that traditionally received very few reports now receives hundreds
 - Statistical Determination

Those are the black & white examples

- More frequently, some combination qualities and quantities of data
 - Medical judgment combined with statistical output

Unite Medical Judgment and Statistical Analyses

- Describe basics of the medical evaluation of an event report
 - What characteristics indicate a safety signal
 - Which of these characteristics are more interesting than others
- System of analytics that results in probabilities
 - $P(\text{observing Product-Event})$ e.g. $P(\text{Tylenol-Headache})$
- Pieces of the Expected Utility puzzle

Anticipated Result

- Consistency
- Efficiency
 - FOCUS TIME ON CASES MOST IN NEED OF REVIEW
- Explicitness
 - Documented priorities
 - Added benefit: Inspection Ready

Idea Generation and Workshop

- Pre-Work: SMEs asked to record 'interesting/eye catching' cases
 - What makes the case medically significant?
 - What makes the case inconsequential?
 - Submitted thoughts to me (independent of one another)
- Day-long workshop
 - Posted factors that affect judgment, e.g.
 - Case is serious
 - Case is rare* for this product
 - Case contains evidence of medical confirmation
 - Case event is labeled/expected
 - Discuss and discuss and discuss
 - *Defined certain ambiguous terms

Prioritization

- Identified 17 factors that were indicative of medically interesting cases
- Some factors were more medically interesting than others
 - Bucket factors into High, Medium, Low informativeness
 - High: Serious
 - Medium: Rechallenge (drug => event STOP drug=> event again)
 - Low: Dechallenge (event stopped when drug stopped)
 - Within each bucket, assign numerical values (Priority Scores) to each factor
 - Value indicates how important the event is for identifying a potential safety signal
 - 9=Very Important to 1=least important
 - Compared Priority Scores across buckets to insure logical consistency
 - “Does it feel right that a serious event is twice as informative as knowing an event is rare (but not serious)”

Compile Priority Scores and Probabilities

- Large computer, expensive software
- Any event may have priority scores for several factors:
 - A serious event that is also rechallenge event
 - Priority scores are added for these (9 for serious plus 5 for rechallenge)
- Probabilities computed (and reversed)
 - Closer the value is to 1.0, the more statistically unexpected the event
- Review Priority = Priority scores X Probability
 - The higher the value, the more immediate the need for medical review
 - Prioritizes the MASSIVE amounts of events
 - Consistent, efficient, explicit

What worked...what could have been better...what else...

- Seek professional help
 - Consulted with a Pharmacovigilance organization
 - DA not their area of expertise
- Sell it internally
 - Everyone needs to buy-in
 - Statistics will not replace medical judgment
 - One champion is critical, but it takes a village
 - Corporate memory – Levitan *et al.* Drug Safety (2008)
- Future Developments
 - Re-evaluation of prioritization scores
 - Re-evaluation of addition of prioritizations
 - Sensitivity/specificity and data mining
 - Look at growing database of escalated safety events and Review Priorities

Johnson & Johnson

FAMILY OF CONSUMER COMPANIES